InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Ovid Therapeutics Inc.

OVID Clue Score44
United States Fiscal year ends December CIK 0001636651
$2.46 +5.13% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.46 −32.79% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 5 May 2017. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−22.5Net income−22.4Fiscal year 2017Operating income−65.0Net income−64.8Fiscal year 2018Operating income−52.9Net income−52.0Fiscal year 2019Operating income−61.4Net income−60.5Fiscal year 2020Revenue12.6Operating income−81.4Net income−81.0EPS, diluted−1.39Fiscal year 2021Revenue208.4 +1,551.6%Operating income124.2Net income122.8EPS, diluted1.76Fiscal year 2022Revenue1.5 −99.3%Operating income−55.5Net income−54.2 −144.1%EPS, diluted−0.77 −143.8%Fiscal year 2023Revenue0.4 −73.9%Operating income−59.3Net income−52.3EPS, diluted−0.74Fiscal year 2024Revenue0.6 +44.4%Operating income−61.9Net income−26.4Fiscal year 2025Revenue7.3 +1,181.3%Operating income−42.4Net income−17.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 12.6 208.4 1.5 0.4 0.6 7.3
Growth +1,551.6% −99.3% −73.9% +44.4% +1,181.3%
Operating income −22.5 −65.0 −52.9 −61.4 −81.4 124.2 −55.5 −59.3 −61.9 −42.4
Net income −22.4 −64.8 −52.0 −60.5 −81.0 122.8 −54.2 −52.3 −26.4 −17.4
Growth −144.1%
EPS, diluted n/a n/a n/a n/a −1.39 1.76 −0.77 −0.74 n/a n/a
Growth −143.8%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Operating margin−645.4%Net margin−642.3%Free cash flow margin−409.8%Fiscal year 2021Operating margin59.6%Net margin58.9%Free cash flow margin56.8%Fiscal year 2022Operating margin−3,696.4%Net margin−3,604.7%Free cash flow margin−3,756.6%Fiscal year 2023Operating margin−15,122.7%Net margin−13,351.8%Free cash flow margin−11,689.0%Fiscal year 2024Operating margin−10,933.7%Net margin−4,670.1%Free cash flow margin−9,898.8%Fiscal year 2025Operating margin−585.2%Net margin−240.1%Free cash flow margin−528.6%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −645.4% 59.6% −3,696.4% −15,122.7% −10,933.7% −585.2%
Net margin n/a n/a n/a n/a −642.3% 58.9% −3,604.7% −13,351.8% −4,670.1% −240.1%
Free cash flow margin n/a n/a n/a n/a −409.8% 56.8% −3,756.6% −11,689.0% −9,898.8% −528.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−17.8Capital expenditure−0.0Free cash flow−17.8Fiscal year 2017Operating cash flow−31.5Capital expenditure−0.0Free cash flow−31.5Fiscal year 2018Operating cash flow−45.6Capital expenditure−0.0Free cash flow−45.6Fiscal year 2019Operating cash flow−51.1Capital expenditure−0.1Free cash flow−51.1Fiscal year 2020Operating cash flow−51.6Capital expenditure−0.1Free cash flow−51.7Fiscal year 2021Operating cash flow118.6Capital expenditure−0.2Free cash flow118.4Fiscal year 2022Operating cash flow−55.2Capital expenditure−1.2Free cash flow−56.5 −147.7%Fiscal year 2023Operating cash flow−45.8Capital expenditure−0.0Free cash flow−45.8Fiscal year 2024Operating cash flow−56.0Capital expenditure−0.1Free cash flow−56.0Fiscal year 2025Operating cash flow−38.3Capital expenditure0.0Free cash flow−38.3
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −17.8 −31.5 −45.6 −51.1 −51.6 118.6 −55.2 −45.8 −56.0 −38.3
Capital expenditure −0.0 −0.0 −0.0 −0.1 −0.1 −0.2 −1.2 −0.0 −0.1 0.0
Free cash flow −17.8 −31.5 −45.6 −51.1 −51.7 118.4 −56.5 −45.8 −56.0 −38.3
Growth −147.7%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash51.9Shareholders’ equity49.3Fiscal year 2017Cash87.1Shareholders’ equity83.4Fiscal year 2018Cash36.5Shareholders’ equity38.8Fiscal year 2019Cash41.9Shareholders’ equity70.0Fiscal year 2020Cash72.0Shareholders’ equity43.6Fiscal year 2021Cash187.8Shareholders’ equity179.7Fiscal year 2022Cash44.9Shareholders’ equity132.3Fiscal year 2023Cash27.0Shareholders’ equity87.8Fiscal year 2024Cash26.3Shareholders’ equity68.2Fiscal year 2025Cash13.2Shareholders’ equity130.7
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 51.9 87.1 36.5 41.9 72.0 187.8 44.9 27.0 26.3 13.2
Shareholders’ equity 49.3 83.4 38.8 70.0 43.6 179.7 132.3 87.8 68.2 130.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−17.8 −31.5 −45.6 −51.1 −51.6 118.6 −55.2 −45.8 −56.0 −38.3
Growth −146.6%
0.1 0.1 0.1 0.3 0.3 0.2 0.5 0.6 0.6 0.3
Investment
−0.0 −0.0 −0.0 −0.1 −0.1 −0.2 −1.2 −0.0 −0.1 0.0
calc −17.8 −31.5 −45.6 −51.1 −51.7 118.4 −56.5 −45.8 −56.0 −38.3
Growth −147.7%
calc n/a n/a n/a n/a −0.88 1.74 −0.80 −0.65 n/a n/a
n/a −0.0 −5.4 −30.0 34.6 −1.8 −87.9 −2.6 54.6 −49.9
Financing
n/a 66.7 0.3 86.5 47.1 0.9 0.2 30.5 0.6 75.2

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.